S
Sarah C. Shuck
Researcher at Beckman Research Institute
Publications - 31
Citations - 592
Sarah C. Shuck is an academic researcher from Beckman Research Institute. The author has contributed to research in topics: Medicine & DNA repair. The author has an hindex of 8, co-authored 22 publications receiving 491 citations. Previous affiliations of Sarah C. Shuck include Indiana University & Vanderbilt University.
Papers
More filters
Journal ArticleDOI
Eukaryotic nucleotide excision repair: from understanding mechanisms to influencing biology
TL;DR: The impact of NER on carcinogenesis, neurological function, sensitivity to environmental factors and sensitivity to cancer therapeutics, as well as from reconstitution studies and structural analyses of the proteins and enzymes that participate in this pathway are discussed.
Journal ArticleDOI
Targeted inhibition of Replication Protein A reveals cytotoxic activity, synergy with chemotherapeutic DNA-damaging agents, and insight into cellular function.
Sarah C. Shuck,John J. Turchi +1 more
TL;DR: A novel small molecule is identified that inhibits the in vitro and cellular ssDNA-binding activity of RPA, prevents cell cycle progression, induces cytotoxicity, and increases the efficacy of chemotherapeutic DNA-damaging agents.
Journal ArticleDOI
Identification of Novel Small Molecule Inhibitors of the XPA Protein Using in Silico Based Screening
TL;DR: Small molecule inhibitors of the DNA binding activity of the xeroderma pigmentosum group A protein are identified and characterized in silico screening of a virtual small molecule library resulted in the identification of a class of molecules confirmed to inhibit the xingroup A protein-DNA interaction.
Journal ArticleDOI
Targeting the OB-Folds of Replication Protein A with Small Molecules
Victor J. Anciano Granadillo,Jennifer N. Earley,Sarah C. Shuck,Sarah C. Shuck,Millie M. Georgiadis,Richard W. Fitch,John J. Turchi +6 more
TL;DR: Together these data demonstrate that the specific targeting of a protein-DNA interaction can be exploited towards interrogating the cellular activity of RPA as well as increasing the efficacy of DNA-damaging chemotherapeutics used in cancer treatment.
Journal ArticleDOI
DNA Advanced Glycation End Products (DNA-AGEs) Are Elevated in Urine and Tissue in an Animal Model of Type 2 Diabetes
Richard Jaramillo,Sarah C. Shuck,Yin S. Chan,Xueli Liu,Steven E. Bates,Punnajit Lim,Daniel Tamae,Sandrine Lacoste,Timothy R. O'Connor,John Termini +9 more
TL;DR: Urinary CEdG measurement may provide a noninvasive quantitative index of glycemic status and augment existing biomarkers for the diagnosis and monitoring of diabetes.